Loading publications…
The last 5 uploaded publications
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
Eben I. Lichtman, Amit Khot, Bradley Augustson, David Levitz, Hanlon Sia, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Harjeet Sembhi, Maria Pihlgren, Cyril Konto, Beata Holkova, Lida Pacaud, Hang Quach (2025). Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7514.
Article63 days agoAbstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
Andrew Garton, Vinu Menon, Hang Quach, Amit Khot, Brad Augustson, Hanlon Sia, David Levitz, Eben I. Lichtman, Michaela Liedtke, Camille Martinet, Beata Holkova, Lida Pacaud, Sunitha Gn, Maria Pihlgren, Mario Perro, Cyril Konto (2025). Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients. , 85(8_Supplement_2), DOI: https://doi.org/10.1158/1538-7445.am2025-ct147.
Article63 days agoFirst Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Hang Quach, Bradley Augustson, Hanlon Sia, Nishi Shah, Eben I. Lichtman, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Maria Pihlgren, Beata Holkova, Cyril Konto, Lida Pacaud, Amit Khot (2024). First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-208189.
Article63 days ago